MSKCC Foundations in Immunotherapy in the Oncology Population 2026

Categories: - MUS, Allergy & Immunology, Hematology, Immunotherapy, Internal Medicine, Memorial Sloan Kettering Cancer Center (MSKCC CME), Oncology, Uncategorized Tags: advanced immunotherapy education, advanced practice providers oncology, allied health oncology, allied health oncology professionals, bispecific antibodies, BiTE therapy, bladder cancer immunotherapy, breast cancer immunotherapy, breast cancer immunotherapy cfDNA, cancer care professionals, cancer immunotherapy, cancer immunotherapy foundations, cancer treatment professionals, CAR T-cell neurotoxicity, CAR T-cell therapy, cfDNA immunotherapy biomarkers, checkpoint blockade therapy, chimeric antigen receptor T-cell therapy, clinical immuno-oncology updates, clinical immunotherapy updates, CRS management, CTLA-4 inhibition, CTLA-4 inhibitors, cytokine release syndrome, dermatologic toxicity immunotherapy, DLL3 targeted therapy, Dostarlimab MSI-high cancer, Dostarlimab MSI-high cancers, durvalumab adjuvant therapy, durvalumab therapy, foundations in immunotherapy 2026, gastrointestinal cancer immunotherapy, gynecologic cancer CAR T-cell therapy, hematologic malignancy immunotherapy, hematologists, hematology oncology course, Hodgkin lymphoma checkpoint inhibition, Hodgkin lymphoma checkpoint inhibitors, ICANS management, ICANS neurotoxicity, IL-2 stimulating agents, immune checkpoint inhibitors, immune-related adverse events, immuno-oncology, immunotherapy adverse event management course, immunotherapy evidence-based practice, immunotherapy for oncologists, immunotherapy mechanisms of action, immunotherapy oncology CME 2026, immunotherapy toxicity management, immunotherapy training, immunotherapy-related pneumonitis, intrathecal immunotherapy, irAE management, leptomeningeal disease immunotherapy, leukemia immunotherapy, lymphoma immunotherapy, medical oncology course, medical oncology training, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering CME, Memorial Sloan Kettering immuno-oncology, Memorial Sloan Kettering immunotherapy program, MSI-high tumor treatment, MSKCC, MSKCC cancer immunotherapy, MSKCC CAR T-cell therapy course, MSKCC CAR T-cell therapy education, MSKCC checkpoint inhibitor course, MSKCC checkpoint inhibitor education, MSKCC CME, MSKCC Foundations in Immunotherapy in the Oncology Population 2026, MSKCC immuno-oncology training, MSKCC immunotherapy 2026, MSKCC immunotherapy course, MSKCC oncology CME 2026, MSKCC Oncology Education, multiple myeloma bispecific agents, multiple myeloma bispecific therapy, oncologists, oncologists education, oncology CME, oncology education, oncology nurse practitioner, oncology nurse practitioners, oncology population immunotherapy course, online immunotherapy course, PD-1 inhibitors, PD-L1 inhibitors, physician assistant oncology, physician assistants oncology, prolonged cytopenias, prolonged cytopenias in cell therapy, small cell lung cancer immunotherapy, solid tumor immunotherapy, synovial sarcoma T-cell therapy, TIL therapy, tumor infiltrating lymphocyte therapy Brand: MedicalVideoStore

Description

Description

+ Include: 23 Videos (.mp4)+ 23 Subtitles (.vtt) + 20 PDFs, size: 4.97 GB

+ Target Audience: oncologists

+ Information:

1. Overview

The Memorial Sloan Kettering Cancer Center Foundations in Immunotherapy in the Oncology Population 2026 course provides a comprehensive exploration of the principles, clinical applications, and management of immuno-oncology therapies. The program covers checkpoint inhibitors, CAR T-cell therapy, and bispecific agents across various malignancies, while offering evidence-based strategies for recognizing and mitigating immune-related adverse events.

Course Date: Wednesday, January 28, 2026, 8:00 AM – 4:45 PM, Online

Immunotherapeutics have transformed the treatment landscape for patients with both solid tumors and hematologic malignancies. Since the landmark approval of ipilimumab, rapid and ongoing advancements in immunotherapy have continued to revolutionize clinical practice.

This one-day live virtual CME program will provide a comprehensive review of foundational concepts and emerging advances in cancer immunotherapy, tailored to the educational needs of physicians, advanced practice providers (APPs), and allied health professionals. Faculty experts will highlight clinical applications across solid and hematologic cancers, as well as strategies for recognizing and managing toxicity—including immune-related adverse events (irAEs) associated with immune checkpoint inhibition.

Presentations will cover the fundamentals of immune checkpoint blockade and CAR T-cell therapy, along with updates in TIL and BiTE therapies, novel combination approaches, and algorithmic management of irAEs. Toxicity management will be reinforced through case-based discussions illustrating common, rare, and severe presentations.

The goal of this program is to improve patient outcomes by advancing understanding of cancer immunology and enhancing the effective, evidence-based application of immunotherapeutic strategies in clinical practice.

Specialties

Specialties – Dermatology, Genitourinary Oncology, Hematology, Hepatology, Hospitalist, Immunotherapy, Leukemia, Lymphoma, Medical Oncology, Myeloma, Neuro-Oncology, Nurse Practitioner, Physician Assistant, Pulmonary Medicine, Solid Tumor Oncology

2. Learning Objectives

Identify and define foundational concepts of immunotherapy, including key immune system components, mechanisms of action, and types of immunotherapeutic agents.
Explain the biological rationale and mechanisms by which immunotherapy targets solid and hematologic malignancies, distinguishing between innate and adaptive immune responses.
Apply evidence-based immunotherapeutic approaches to the management of solid tumors and hematologic cancers, including appropriate patient selection, risk stratification, and development of individualized treatment plans.
Compare and contrast novel immunotherapy agents, including checkpoint inhibitors, bispecific antibodies, and immune agonists, in terms of efficacy, safety profiles, and mechanisms of action.
Evaluate the role of CAR T-cell therapy in current oncology practice, including patient eligibility, response rates, and long-term outcomes, and design a toxicity management plan for immune-related adverse events (irAEs) in immuno-oncology patients.

3. Target Audience

Best for oncologists and specialized nursing professionals who want foundational updates on immunotherapy protocols and adverse event management.

4. Topics

Advancing CAR T-Cell Strategies and Combination Therapies to Improve Outcomes in Gynecologic Malignancies
Advancing Leukemia Care Through Immuno-Oncology
Approaches to Immunotherapy-related Pneumonitis Management
Breast Oncology- Using cfDNA to Forecast Immunotherapy Treatment Outcomes
Checkpoint Inhibition as a Therapeutic Approach in Advanced Hodgkin Lymphoma
Clinical Approaches to Dermatologic Toxicity in Checkpoint Inhibitor Therapy
Discussion of Novel Checkpoint Inhibitors and Combination Therapy
Dostarlimab in MSI-High Gastrointestinal Cancers- Latest Data, Expansion Cohorts, and Basket Trial Insights
Evolving Treatment Paradigms- Immunotherapy in Advanced Bladder Cancer
IL-2-Stimulating Agents from Early Drug Development
Innovations in Small Cell Lung Cancer- DLL3 Agents and Adjuvant Durvalumab
Intrathecal Immunotherapy- A Novel Path in Treating Leptomeningeal Disease no video
Mechanism of Action of Checkpoint Blockade PD1, PDL1, CTLA-4
Melanoma Subtypes are a Microcosm for Immune Checkpoint Blockade Efficacy Across Oncology-
Neurotoxicity in CAR T-Cell Therapy- Recognition and Management
Overview of Adverse Events in the Cell Therapy Patient- A Discussion of CRS, ICANS, and Prolonged Cytopenias
Q&A and Discussion – 01
Q&A and Discussion – 02
Q&A and Discussion – 03
Q&A and Discussion – 04
Q&A and Discussion
Targeting Multiple Myeloma with Bispecific Immune-Modulating Agents
The Role of T-Cell Therapy in Standard Care for Synovial Sarcoma
Understanding Chimeric Antigen Receptor (CAR) T-Cell Therapy